Drug Trial Radar · NCT03100500
A Long-term Safety Study of QMF149 in Japanese Participants With Asthma
Last checked: Nov 19, 2026Latest source record: Feb 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
51
Actual
Start
Apr 25, 2017
Primary completion
Jul 19, 2018
Study completion Feb 12, 2019
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Apr 4, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to provide long term safety data of QMF149 in Japanese participants with inadequately controlled asthma for the registration of QMF149 in Japan.
Conditions
- Asthma
Interventions
QMF149Drug
QMF149 150/320 μg once daily, delivered as powder in hard capsules via Concept1 inhaler
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: Up to 52 weeks
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Novartis Investigative Site
Nagoya, Aichi-ken, Japan
Novartis Investigative Site
Fukuoka, Fukuoka, Japan
Novartis Investigative Site
Chitose, Hokkaido, Japan
Novartis Investigative Site
Kitahiroshima, Hokkaido, Japan
Novartis Investigative Site
Sapporo, Hokkaido, Japan
Novartis Investigative Site
Sapporo, Hokkaido, Japan
Novartis Investigative Site
Takamatsu, Kagawa-ken, Japan
Novartis Investigative Site
Yokohama, Kanagawa, Japan
Novartis Investigative Site
Yokohama, Kanagawa, Japan
Novartis Investigative Site
Yokosuka, Kanagawa, Japan
Novartis Investigative Site
Chino, Nagano, Japan
Novartis Investigative Site
Higashiosaka, Osaka, Japan
Novartis Investigative Site
Chuo Ku, Tokyo, Japan
Novartis Investigative Site
Chuo-ku, Tokyo, Japan
Novartis Investigative Site
Toshima-ku, Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.